Patients typically notice reduced shedding within the first few weeks, with visible improvement in hair density and thickness developing over the following months
Ro Offers Eli Lilly's Foundayo, the Newest GLP-1 Innovation Foundayo gives patients a new once daily pill option and expands Ros comprehensive weight loss formulary April 9, 2026 Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Companys newest oral GLP-1 innovation on the Ro platform, adding to Ros already comprehensive formulary of FDA-approved GLP-1s
The FDA cleared orforglipron for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, based on the ATTAIN clinical program which showed placebo-adjusted weight loss of 7.5% to 11.2% in non-diabetics (ATTAIN-1) and 5.1% to 9.6% in diabetics at different doses, along with the expected glycaemic benefits (ATTAIN-2)
Avoid products that misuse official logos or cite unverifiable clinical studies
While bariatric surgery remains the most effective method for significant and sustained weight loss, its application is often limited by factors such as the availability of skilled surgeons, high costs, and the potential for postoperative complications 9
That infrastructure made it easy for hundreds of companies to launch or pivot toward GLP-1 prescribing to meet demand quickly
